No Data
Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight
Stoke Therapeutics (STOK) Gets a Buy From Leerink Partners
Stoke Therapeutics Stockholders Approve Directors and Governance Items
Express News | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39